Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Quick facts
Marketed products
- Discontinuation of thiopurines. · Immunology
Discontinuation of thiopurines involves stopping the use of immunosuppressive purine analogs to assess disease control and reduce long-term toxicity risks.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa portfolio CI brief
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa pipeline updates RSS
Frequently asked questions about Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
What are Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa's marketed drugs?
Top marketed products include Discontinuation of thiopurines..
Related
- Discontinuation of thiopurines. · Immunology
- Sector hub: All tracked pharma companies